Use of oral diazoxide for the treatment of disorders in glucose metabolism

• US 5,284,845 A
• Filed: 08/27/1992
• Issued: 02/08/1994
• Est. Priority Date: 03/14/1991
• Status: Expired due to Fees

• Current Assignee: Elsa P. Paulsen
• Original Assignee: Elsa P. Paulsen
• Inventors: Paulsen, Elsa P.
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US07/936,867
• Time in Patent Office: 530 Days
• Field of Search: 514/223.2, 514/866
• US Class Current: 514/223.2
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

A method is disclosed for normalizing blood glucose and insulin levels as measured by an oral glucose tolerance test in an individual exhibiting normal fasting blood glucose and insulin levels and exhibiting in an oral glucose tolerance test elevated glucose levels and at least one insulin level abnormality selected from the group consisting of a delayed insulin peak, an exaggerated insulin peak and a secondary elevated insulin peak. The method comprises administering diazoxide to the individual before ingestion of a food source in an amount effective to normalize the blood glucose and insulin levels. Diazoxide is administered in an amount from about 0.4 to about 0.8 mg/kg body weight before each meal.

Claims

1. A method for normalizing blood glucose and insulin levels as measured by an oral glucose tolerance test in an individual exhibiting normal fasting blood glucose and insulin levels and exhibiting in an oral glucose tolerance test elevated glucose levels and at least one insulin level abnormality selected from the group consisting of a delayed insulin peak, an exaggerated insulin peak and a secondary elevated insulin peak, said method comprising administering diazoxide to said individual before ingestion of a food source in an amount effective to normalize said blood glucose and insulin levels, wherein said diazoxide is administered in an amount from about 0.4 to about 0.8 mg/kg body weight before each meal.

2. A method according to claim 1 wherein said insulin level abnormality in a secondary elevated insulin peak, and wherein said individual exhibits in an oral glucose tolerance test three insulin peaks at about 30 minutes, about 90 minutes and about 3 hours and two elevated glucose peaks at about 30 to about 60 minutes and at about 2 hours to about 2.5 hours.

3. A method according to claim 1 wherein said insulin level abnormality is a delayed insulin peak, and wherein said individual exhibits in an oral glucose tolerance test a poor first insulin peak followed by said delayed insulin peak at about 90 minutes and an elevated glucose peak at about 60 to about 90 minutes after said delayed insulin peak.

4. A method according to claim 1 wherein said insulin level abnormality is a secondary elevated insulin peak, and wherein said individual exhibits in an oral glucose tolerance test an initial insulin peak followed by a second peak at about 90 minutes and a third peak at about 2.5 hours and hypoglycemia at about 3 hours to about 3.5 hours.

5. A method according to claim 1 wherein said diazoxide is administered orally.

6. A method according to claim 1 wherein said administration of diazoxide causes the magnitude of said blood insulin and glucose levels to approximate more closely the normal pattern.

7. A method according to claim 1 wherein said administration of diazoxide causes the timing of peaks in said blood insulin and glucose levels to approximate more closely the normal patterns.

8. A method according to claim 1 wherein said diazoxide is administered within 30 minutes before a meal.

9. A method according to claim 8 wherein said diazoxide is administered about 10 to about 15 minutes before a meal.